Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report

Adenocarcinoma Harboring EGFR-RAD51 Fusion Treated With Osimertinib: A Case Report

EGFR mutations are among the most common driver mutations in lung adenocarcinoma. Rare alterations, such as the EGFR-RAD51 fusion, respond to treatment with EGFR tyrosine kinase inhibitors but can be missed by limited genomic sequencing panels. Here, we report a case of metastatic lung adenocarcinom...

Full description

Bibliographic Details
Main Authors: Sunny Y. Lai, MD, Noah H. Richardson, MD, Mya Tran, PharmD, Nasser H. Hanna, MD, Misty D. Shields, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JTO Clinical and Research Reports
Subjects:
Non–small cell lung cancer
EGFR fusion
TKI
Case report
NGS
Osimertinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000225

Similar Items

Similar Items